Evidence map›Paper›PMID 23144720›Full record

ArticlePloS one2012

Identification of She3 as an SCF(Grr1) substrate in budding yeast.

Ruiwen Wang, Mark J Solomon

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ruiwen WangDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut, United States of America.
Mark J Solomon
Yale University · US

Funding

Anaphase Promoting Complex-mediated ProteolysisR01GM076200 · NIGMS · YALE UNIVERSITY · PI SOLOMON, MARK J · 2006 to 2009
$1.6M
Pseudosubstrate Inhibition of the Anaphase Promoting ComplexR01GM088272 · NIGMS · YALE UNIVERSITY · PI SOLOMON, MARK J · 2009 to 2010
$662k
NIGMS NIH HHS GM76200NIGMS NIH HHS GM88272NIGMS NIH HHS R01 GM076200NIGMS NIH HHS R01 GM088272
6 · The paper itself

Abstract

The highly orchestrated progression of the cell cycle depends on the degradation of many regulatory proteins at different cell cycle stages. One of the key cell cycle ubiquitin ligases is the Skp1-cullin-F-box (SCF) complex. Acting in concert with the substrate-binding F-box protein Grr1, SCF(Grr1) promotes the degradation of cell cycle regulators as well as various metabolic enzymes. Using a yeast two-hybrid assay with a Grr1 derivative as the bait, we identified She3, which is an adaptor protein in the asymmetric mRNA transport system, as a novel Grr1 substrate. We generated stabilized She3 mutants, which no longer bound to Grr1, and found that the degradation of She3 is not required for regulating asymmetric mRNA transport. However, She3 stabilization leads to slower growth compared to wild-type cells in a co-culture assay, demonstrating that the degradation of She3 by Grr1 is required for optimal cell growth.

Indexed as

F-Box ProteinsImmunoblottingMicroscopy, FluorescenceMutationMyosin Heavy ChainsMyosin Type VProtein BindingProteolysisRepressor ProteinsRNA-Binding ProteinsSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSubstrate SpecificityTwo-Hybrid System TechniquesUbiquitin-Protein LigasesASH1 protein, S cerevisiaeF-Box ProteinsGRR1 protein, S cerevisiaeMyo4 protein, S cerevisiaeMyosin Heavy ChainsMyosin Type VRepressor ProteinsRNA-Binding ProteinsSaccharomyces cerevisiae ProteinsSHE2 protein, S cerevisiaeSHE3 protein, S cerevisiaeUbiquitin-Protein Ligases

Identifiers

PMID23144720
PMCPMC3483296
OpenAlexW2016963498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.